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Abstract: Through a simple 1,3-cycloaddition reaction, three BODIPY-peptide conjugates that target
the extracellular domain of the epidermal growth factor receptor (EGFR) were prepared and their
ability for binding to EGFR was investigated. The peptide ligands K(N3 )LARLLT and its cyclic analog
cyclo(K(N3 )larllt, previously shown to have high affinity for binding to the extracellular domain of
EGFR, were conjugated to alkynyl-functionalized BODIPY dyes 1 and 2 via a copper-catalyzed click
reaction. This reaction produced conjugates 3, 4, and 5 in high yields (70–82%). In vitro studies using
human carcinoma HEp2 cells that overexpress EGFR demonstrated high cellular uptake, particularly
for the cyclic peptide conjugate 5, and low cytotoxicity in light (~1 J·cm−2 ) and darkness. Surface
plasmon resonance (SPR) results show binding affinity of the three BODIPY-peptide conjugates for
EGFR, particularly for 5 bearing the cyclic peptide. Competitive binding studies using three cell
lines with different expressions of EGFR show that 5 binds specifically to EGFR-overexpressing colon
cancer cells. Among the three conjugates, 5 bearing the cyclic peptide exhibited the highest affinity
for binding to the EGFR protein.

Dipyrromethene (BODIPY)
Fluorophores to EGFR-Targeting
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The study of protein–protein interactions (PPIs) is very useful when investigating mutagenic behaviors that lead to diseases and oncogenic mutations [1–3]. Several studies offer
insight on the behavior of PPIs in human diseases, in particularly oncogenic mutations of
the epidermal growth factor receptor (EGFR) in colorectal cancer (CRC) [4]. This mutation
makes targeting EGFR for CRC detection very attractive. To capitalize on this strategy,
recent studies have targeted EGFR, as a method to increase tumor cell specificity for cancer
therapy [4–7]. Practices including FDA-approved anti-EGFR antibody cetuximab [8,9],
single-chain anti-EGFR ScFvEGFR [10–12], anti-EGFR affibody [13,14], accessible small
peptides [15], and tyrosine kinase inhibitors [16,17] have all been employed to understand
targeting EGFR.
EGFR is a ligand-stimulated receptor that holds a crucial role in regulating cellular
functions, more directly comprising cell proliferation and survival [4–7,18]. In addition,
EGFR houses a single polypeptide backbone chain that is understood to be an important
component in exploring effective treatments and screening of cancers, such as CRC. While
the overexpression of EGFR on the surface of CRC is due to mutations in the gene, and
its upregulation, the activation of EGFR can also occur through mutation in the kinase
domain [17,18].
While current research has identified several practices for targeting EGFR, our group
has previously prepared and investigated EGFR-targeted porphyrin-peptide [19], phthalocyanine-peptide [20], and BODIPY-peptide conjugates [21–23]. In those studies, two small
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peptides reported in the literature, designated EGFR-L1 (LARLLT) [24] and EGFR-L2 (YHWYGYTPQNVI) [25], showed to have high EGFR specificity both in in vitro and in vivo
studies, were used. The conjugates linked to EGFR-L1 via a short PEG linker showed
enhanced water solubility when compared with the conjugates attached to EGFR-L2, which
bears a longer hydrophobic peptide sequence [20,21]. Additionally, these peptide-bearing
conjugates showed enhanced EGFR-targeting ability, and up to 90-fold increased accumulation in EGFR-overexpressed cells compared with unconjugated fluorophore [21]. These
results suggest that fluorophores conjugated to EGFR-L1 and EGFR-L2 have substantially
increased EGFR- targeting ability and may be very useful for the early detection and
diagnosis of CRC and other EGFR-overexpressing cancers. While EGFR-L1 is known to
bind in domain I of EGFR, away from the EGF binding pocket, EGFR-L2 binds to the
EGF binding pocket on the extracellular domain of EGFR. Furthermore, previous studies
suggest that EGFR-L1 conjugates tend to bind to EGFR with higher affinity compared
with the EGFR-L2-based conjugates [19,20,26]. This might be a result of EGFR-L1 binding
away from the EGF binding pocket, allowing for interactions with various conformations
of EGFR, as the binding site for EGFR-L1 in domain I is not affected by conformational
changes in EGFR [19].
Designing a fluorophore that is robust enough to handle the biological framework
of CRC requires the scaffold to be robust, easily assembled, and visible enough to ensure
proper screening. One must consider the development of these types of compounds
to ensure stability and biocompatibility. Peptides bear an amine or carboxyl terminus
available for conjugation to fluorophores such as porphyrins, phthalocyanines and boron
dipyrromethenes (BODIPYs). BODIPYs are extremely useful fluorophores because of their
tunable core structure and excellent photophysical properties [27–29]. Research shows
that BODIPYs maintain a highly spectroscopic tunable core that is stable under various
conditions. Increasing efficient approaches for conjugating BODIPY dyes to peptides
requires that a clear position for attachment be available at each molecule. In peptide
synthesis, the most evident attachment point is the exposed free amino group at the Nterminus of the sequence that can be used in traditional conjugation through amidation.
Over time research has recognized the simplicity in forming attachment points during
peptide synthesis (amines), however, the required carboxyl component on BODIPY dyes is
not as easily attained, and the conjugation yields are moderate to low [23]. Therefore, a
simple and high-yielding conjugation method, such as a so-called “click” reaction [30,31]
has become more attractive in the last decade.
The copper(I)-catalyzed azide-alkyne cycloadditions, or click reactions, have a multitude of suitable features, including mild reaction conditions, short completion times, simple
to no purification required, and high stability of the resulting triazoles under various reaction conditions, such as to air and moisture. Because of these benefits, the 1,3-dipolar
cycloaddition is very attractive to researchers performing porphyrinoid conjugations for
use in imaging and photodynamic therapy [32–35]. Even more striking is that this cycloaddition is especially fitting for sensitive constituents such as peptides, carbohydrates,
and nucleotides. The overall attraction of click chemistry is deep-rooted in its nature to
be selective, mild, and adaptable [36–38]. Other key components of click reactions lie in
their ability to be nearly quantitative through the robust behavior and insensitivity of the
resulting triazoles to various conditions [37]. The orthogonal ligation that occurs is suitable
for various biomolecular pairing and in vivo labeling. The 1,2,3-triazoles formed in this
reaction are stable under acidic and basic conditions, reductive and oxidative environments,
and are resistant to proteolytic cleavages [38]. In addition, triazoles are also resilient to
metabolic degradation. Overall, the steady nature of click compounds creates an ideal
platform for developing stable fluorophore conjugates for bioimaging applications.
Previous studies report the use of BODIPY dyes as the fluorescent component in
cell-targeted conjugates bearing various targeting moieties for use in in vivo imaging. For
example, Wolfbeis et al. [39] reported fluorescently labeled biomolecules through the use
of copper-free and copper-mediated click chemistry. Wolfbeis et al. designed clickable

Molecules 2021, 26, 593

3 of 14

BODIPY fluorophores for labeling of the azide-modified surface glycans of CHO cells.
Akkaya et al. [40] used click chemistry in the synthesis of a bay region BODIPY dye
attached to a perylenediimide (PDI). Akkaya et al. envisioned the molecule suitable for
light harvesting which allows a large cross-section for the absorption of visible light. These
studies were able to show that the excitation energy was efficiently channeled to the PDI
core. Overkleeft et al. [41] designed three acetylene-functionalized BODIPY dyes to identify
an azido-bearing epoxomicin analogue by fluorescence. Overkleeft et al. performed the
functionalization through the Huisgen 1,3-dipolar cycloaddition, which yielded a group of
fluorescent epoxomicin-derived proteasome probes.
We have previously reported the conjugation of BODIPYs to the EGFR-L1 peptide
via traditional amidation reactions [23], and nucleophilic additions to isothiocyanatofunctionalized fluorophores [21,22]. Herein we report the use of click chemistry for conjugation of two EGFR-L1-derived peptides bearing an azide N-terminus (cycloL1.1 and
L1.5) [26] to alkynyl-functionalized BODIPYs. The use of click chemistry allowed the
employment of mild reaction conditions that are compatible with the BODIPY and peptide
scaffolds, increasing the conjugation yield over alternative methodologies, and simplifying conjugate purification. We have previously used click chemistry to conjugate low
molecular weight PEG groups and carbohydrates to BODIPYs, for enhanced aqueous
solubility and cellular permeability [42]. Furthermore, to increase the stability of peptides
in vivo we introduced conformational and configurational constraints, including sequence
cyclization and change in the chirality of amino acids. The structure-activity investigation
of the EGFR-L1 peptide with key modifications in its structure is described in our earlier
report [26]. The modified peptide L1.5 exhibited increased affinity for EGFR compared
to the parent peptide, while cycloL1.1 also exhibited enhanced stability in human serum.
Herein we report the synthesis of two BODIPYs bearing an alkynyl handle for conjugation
via an azide-functionalized lysine side chain to two EGFR-L1 peptide derivatives that have
shown increased EGFR binding affinity and stability relative to EGFR-L1.
2. Results and Discussion
2.1. Synthesis
The alkynyl-functionalized BODIPYs 1 and 2 used in the conjugation reactions were
synthesized as we have previously reported [42]. In brief, p-propargyloxy-benzaldehyde
reacted with 3-ethyl-2,4-dimethylpyrrole in the presence of BF3 ·OEt2 , followed by DDQ
oxidation and boron complexation, to afford BODIPY 1 in 40% yield (see Supporting
Information). Near-IR absorbing and emitting BODIPY 2 was prepared from 1 using
indole-3-carbaldehyde in a Knoevenagel condensation [43]. Styryl-derived BODIPY compounds exhibit significant red-shifted fluorescence emissions due to the extension of the
π-conjugation (Scheme 1). Additionally, the incorporation of an indole moiety has been
observed to induce enhanced solubility and cellular permeability, possibly due to its resemblance to tryptophan. Tryptophan is a naturally occurring amino acid and an important
component of many enzymes and proteins [44]. Therefore, the attachment of a single
indolyl styryl group to the BODIPYs’ core results in an asymmetric mono-styryl BODIPY
that displays a ca. 90 nm bathochromic shift on its absorption and emission profiles, and
also enhanced solubility, cellular permeability, and overall biological efficacy [42,45].
The Knoevenagel reaction of BODIPY 1 in the presence of indole-3-carbaldehyde,
piperidine, and glacial acetic acid in refluxing toluene, using a Dean-Stark apparatus,
afforded the mono-styryl BODIPY 2 in 28–36% yields, due to the concomitant formation of
the distyryl derivative.
The EGFR-targeting peptide ligand EGFR-L1 (LARLLT) was reported in 2009 by Song
et al. [24] and showed to have high affinity for the extracellular domain of EGFR, both
in vitro and in vivo. In previous work, we reported the conjugation of this peptide to a
porphyrin [19], phthalocyanine [20], and BODIPY dyes [21–23], using either traditional
amidation methodologies or nucleophilic addition to isothiocyanato-functionalized fluorophores. These studies indicated that the mode of conjugation significantly influences
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the binding affinity of the resulting conjugates to EGFR. In order to conjugate EGFR-L1 to
BODIPYs 1 and 2 using click chemistry, we modified the EGFR-L1 peptide via the introduction of an azide-functionalized lysine residue, to form L1.5 (K(N3 )LARLLT) (Figure 1) [26].
In addition, to improve the stability of the L1.5 peptide in vivo, we performed a cyclization
reaction to afford cycloL1.1 (cyclo(K(N3 )larllt). Our previous investigations of peptides
Molecules 2021, 26, x FOR PEER REVIEW
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resulting mixture followed by the addition of 1 equivalent of CuSO4 ·5H2 O and L-ascorbic
acid in distilled water. The catalytic amount of copper metal was added as a suitable
reductant for the Cu(II) source, CuSO4 ·5H2 O, in an aqueous solution to generate Cu(I),
which is a potent stimulus for the formation of 1,2,3-triazoles. The reaction was allowed to
stir for 24 h, monitored by MALDI-TOF mass spectrometry. Once the desired product was
confirmed, the mixture was quenched with water. Initially, the resulting conjugate was
purified through a molecular weight cut off (MWCO) tube of 1000 Daltons. This method
was used to retain the conjugate in the tube, as the molecular weight for the desired product
conjugates are all above this value, and any starting materials remaining in the mixture
were removed. The resulting conjugates were dried and purified by RP-HPLC, eluted with
Molecules 2021, 26, x FOR PEER REVIEW
7 of 19
a 1% TFA in H2 O/0.1% TFA in CH3 CN gradient (see Supporting Information) to afford the
corresponding 1,2,3-triazole cycloadducts 3, 4, and 5 in excellent yields (Table 1).
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BODIPY 1 was found to have excitation and emission maxima in the visible region of the
electromagnetic spectrum at 525 and 540 nm, respectively. Extension of the π-conjugation
system of the BODIPY through styryl functionalization via Knoevenagel condensation
resulted in bathochromic shifts to 614 nm excitation and 648 nm emission maxima. As
expected, the absorption and emission maxima did not change significantly after click
conjugation with either the linear or cyclic peptides. Multiple shoulder peaks present in
the absorption spectra of 4 and 5 reflect the possibility of electronic transitions between
differing vibrational energy levels.
2.3. Surface Plasmon Resonance (SPR) Studies
We have previously explored the specificity of peptides L1.5 and cycloL1.1 for EGFR
and determined that they both have a fast association with the EGFR protein’s extracellular
domain through SPR studies [26]. To compare the binding affinity of the BODIPY-peptide
conjugates 3–5 to EGFR in comparison to the peptide sequences alone, SPR [47,48] analyses
were performed. All BODIPY-peptide conjugates and precursors were tested at concentrations up to 250 µM, and the results obtained are shown in Figures S10–S12 of the Supporting
Information. Conjugates 3, 4, and 5 were diluted to desired concentrations with a solution
of running buffer HBS-EP+ containing 8% of DMSO.
For conjugate 5, binding began at around 10 µM and further addition of conjugate
did increase the sensorgram in a stepwise fashion, as seen in Figure S12 (Supplementary
Materials). On the other hand, conjugate 3 binding changes in response began around
10 µM (Figure S10, Supplementary Materials) and there was a stepwise increase in the
sensorgram with smooth association and dissociation with a total change of 450 RU,
suggesting specific binding of the conjugate to the EGFR protein. At 250 µM, conjugate
4 showed a decrease in RU due to a saturation of binding (Figure S11, Supplementary
Materials). On the other hand, conjugate 5 exhibited stepwise increase in binding from 25
to 250 µM concentrations (Figure S12, Supplementary Materials). Moreover, conjugate 5
sensorgram exhibited a smooth (and slow) increase in RU from 100 to 180 sec suggesting
specific binding of conjugate to the EGFR extracellular domain, as shown with peptide
cycloL1.1 [26]. Among the three conjugates studied, 3 and 5 exhibited relatively higher and
specific binding to the EGFR protein. This is similar to what we observed for the free cyclic
peptide which was characterized by a stepwise increase in binding with a slow and even
increase in RU, rather than a rapid increase in the response units.
2.4. Cell Studies
To assess the biological efficacy and behavior of the peptide-functionalized BODIPY
conjugates, preliminary in vitro cellular studies, including dark cytotoxicity, phototoxicity
and cellular uptake, were investigated against human squamous cell carcinoma HEp2 cell
line, with high EGFR expression (~75%).
2.4.1. Dark Toxicity
The dark toxicity of all compounds was determined in HEp2 cells at concentrations up
to 200 µM, using a CellTiter Blue (CTB) assay to determine cell viability. The results from
these studies are shown in Figure 2. BODIPYs 1 and 2 (lacking peptide) were included
in this study for comparison purposes. Interestingly, BODIPY 1 and conjugate 3, both
devoid of styryl and indole functionalities, were the least toxic compounds in this series.
Conjugates 4 and 5 were found to be more cytotoxic than conjugate 3, with calculated IC50
values of approximately 100 µM. On the other hand, BODIPY 2 bearing an indolyl styryl
group was also found to be more toxic than 1. These results suggest that the indolyl styryl
moiety lends some cytotoxicity to compounds containing this functional group. This might
be a result of the presence of the indole group, since it is a known pharmacophore and
the basis of many drugs, such as indomethacin [44,49]. Conjugates 4 and 5 containing the
linear and cyclic peptides, respectively, were found to have similar cytotoxicities, with the
compound containing the cyclic peptide having slightly higher cytotoxicity than its linear
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increase
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when compared to 1 and 3,
which
lackuptake
the indolyl
styryl
group. Interestingly,
conjugate
4 containing
Cellular
studies of
all compounds
were conducted in
a time-dependent
manner.

Cellular uptake was determined in human carcinoma HEp2 cells over a 24 h time period
at a non-toxic concentration of 10 µM for all compounds. A CyQuant® cell proliferation
assay was employed to determine cell numbers. The results from these studies are shown
in Figure 3. BODIPYs 1 and 2 were also investigated to compare their cellular uptake
with that of the peptide conjugates. After the addition of peptide-containing conjugates 4
and 5 to HEp2 cells, kinetics showed a marked uptake increase and rapid accumulation
in cells in less than 4 h, after which a plateau in uptake is observed for the remaining of
the 24 h time period. On the other hand, conjugate 3 and its parent BODIPY 1, which are
devoid of the indolyl styryl moiety, showed the lowest uptake in HEp2 cells. BODIPY 2
showed slightly higher uptake in HEp2 cells compared with 1 as a result of its indolyl styryl
group. However, conjugates 4 and 5 containing the linear and cyclic peptide sequences,
respectively, showed significant higher uptake compared with conjugate 3 in HEp2 cells,
up to 7-fold increase in uptake. Both of these conjugates were readily taken up by HEp2
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cells, with conjugate 5 showing the greatest uptake by far in this series. This result might be
due to the higher affinity of the cyclic peptide for binding to EGFR. We previously reported
that the D-amino acids in cyclo(K(N3 )larllt) and its cyclic structure confer a more rigid
conformation relative to the linear peptide that is more suitable for binding to domain I
of EGFR [26]. In addition, the greater stability of the cyclic peptide might confer higher
stability to conjugate 5 compared with 4, thus allowing for a sustained higher uptake
Molecules 2021, 26, x FOR PEER REVIEW
11 of 19
within cells over time. This observed enhanced cellular uptake for 5 may also contribute to
its observed increase in photo- and dark-toxicity.
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with the highest EGFR expression. When similar experiments were carried
out in the presence of LOVO cells, there was no dose-dependent decrease
in fluorescence intensity suggesting that both 5 and cyclic peptide bind
only non-specifically to the LOVO cells. These results show that conjugate
5 binds specifically to EGFR over-expressing colon cancer cells.
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USA). Column chromatography was performed on silica gel (Sorbent Technologies, 60 Å,
40–63 µm). 1 H-NMR and HSQC spectra were recorded using a Bruker AVIII-500 spectrometer (Birrica, MA, USA) (operating at 500 MHz for 1 H-NMR and HSQC) in DMSO-d6 . All
chemical shifts are given in parts per millions (ppm) relative to tetramethylsilane (TMS,
0 ppm). All spectra were recorded at 308 K. High resolution mass spectra were obtained
at the LSU Department of Chemistry Mass Spectrometry Facility using Bruker Omniflex
MALDI Time-of-Flight Mass Spectrometer. The absorption measurements were carried
out on a Varian 212 Cary 50 UV/Vis spectrophotometer (Palo Alto, CA, USA) and the
steady-state fluorescence spectroscopic studies were performed on a PTI Quantum Master4/2006SE spectrofluorometer (Northampton, UK). All spectra were recorded at 298 K
using non-degassed samples, spectroscopic grade solvents, and a 10-mm quartz cuvette.
RP-HPLC was used to purify BODIPY-peptide conjugates, as shown in our previous work.
The RP-HPLC system is comprised of a 2489 UV/Vis detector, a 2545 quaternary gradient
module pump, and a FlexInject sample injector (Waters, Milford, MA, USA) to a purity of
≥95% (unless otherwise noted). To achieve full separation, X-Bridge BEH300 Prep C18
column (5 µm, 10 × 250 mm) armed with an X-Bridge BEH300 Prep guard column (300 Å,
5 µm, 10 × 10 mm) operating at a gradient of 50% A for 5 min, 50% A to 10% A over 1 min,
10% A to 0% A over 13 min, 0% A to 50% A over 2 min, then hold at 50% A for 5 min at a
flow rate of 4 mL/min (unless otherwise noted). Conjugates UV detection was recorded for
peptides at 220 nm, and for BODIPY at 540 and 640 nm. Fractions of HPLC purity (>95%)
with the anticipated mass were combined and lyophilized. The chromatographs were
analyzed using Empower 2 software. BODIPYs 1 and 2 were synthesized as previously
described in the literature [42] (see Supplementary Materials). Peptides L1.5 and cycloL1.1
were synthesized as previously reported [26].
General Procedure for 1,3-cycloaddition: Alkynyl-functionalized BODIPY and azido-peptide
(1.5 equiv.) were dissolved in a mixture of THF/H2 O (1.8 mL, 3:1), followed by addition
of Cu(0) (1.0 equiv.). A solution of CuSO4 ·5H2 O (1 equiv.) and L-ascorbic acid (1 equiv.)
in H2 O was added to the reaction mixture. The solution was allowed to stir at room
temperature for 24 h. Once the reaction was complete, the mixture was quenched with
water and lyophilized. The fluffy product was then purified by RP-HPLC under varying
gradients of water (with 0.1% TFA) and acetonitrile (with 0.1% TFA).
Conjugate 3 (1,3,5,7-tetramethyl-2,6-diethyl-8-(4-phenoxymethyltriazole K(N3 )LARLLT)-BODIPY):
This conjugate was obtained as a reddish orange solid (4.8 mg, 82%). MALDI-TOF m/z
1273.82; calc. for C63 H100 BF2 N16 O9 + : 1273.79. For 1 H-NMR and HSQC see Supporting
Information.
Conjugate 4 (1,3,7-trimethyl-5-indolylstyryl-2,6-diethyl-8-(4-phenoxymethyltriazole K(N3 )LARLLT)BODIPY): This conjugate was obtained as a dark blue solid (3.49 mg, 70%). MALDI-TOF
m/z 1400.87; calc. for C73 H106 BF2 N16 O9 + : 1400.89. For 1 H-NMR and HSQC see Supporting
Information.
Conjugate 5 (1,3,7-trimethyl-5-indolylstyryl-2,6-diethyl-8-(4-phenoxymethyltriazole cycloK(N3 )larllt)BODIPY): This conjugate was obtained as a deep blue solid (6.1 mg, 80%). MALDI-TOF
m/z 1383.91; calc. for C72 H102 BF2 N16 O9 + : 1383.81. For 1 H-NMR and HSQC see Supporting
Information.
3.2. Spectroscopy Studies
UV-Visible and emission spectroscopy studies were measured using a Varian Cary
spectrophotometer (Palo Alto, CA, USA) and a Perkin Elmer LS55 spectrophotometer
(Waltham, MA, USA) at room temperature. Quartz cuvettes (1 cm path length) were used
for each study. To analyze the data, integrated absorbance against the corresponding
solution concentrations were plotted to conclude the extinction coefficients (ε) at the
maximum absorption.
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3.3. Surface Plasmon Resonance (SPR) Studies
Surface plasmon resonance analysis was conducted using the extracellular domain of
EGFR protein (Leinco Technologies, St. Louis, MO, USA) immobilized on a CM5 sensor
chip via standard amine coupling with a Biacore X100 (GE Healthcare Life Sciences, Marlborough, MA, USA) as described in our previous publications [22,26]. The running buffer
used was 8% DMSO in 1X HBS-EP+ (0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, 0.005%
Tween, pH 7.5) (GE Healthcare Biosciences, Chicago, IL, USA), at a flow rate of 5 µL/min.
DMSO was added to the running buffer and peptide solutions to enhance the solubility
of the peptides studied. The solutions were prepared in running buffer and filtered using
a 0.45 µm filter. All SPR sensorgrams relay the rates of association and dissociation of
analytes at concentrations of 0 to 250 µM performed at room temperature.
3.4. Cell Studies
For cellular studies, commercially available reagents and culture media were purchased from Life Technologies (Carlsbad, CA, USA) and human carcinoma HEp2 (ATCC
CCL-23) cells were purchased from the American Type Culture Collection (ATCC) (Manassas, Virginia, USA). HEp2 cells were cultured and maintained at 37 ◦ C under 5% CO2 and
95% humidity in minimum essential media (MEM) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (P/S).
3.4.1. Dark Cytotoxicity
Stock solutions (32 mM) for compounds 1, 2, 3, 4, and 5 were prepared using 100%
DMSO as the solvent. Working solutions were then prepared at concentrations of 0, 6.25,
12.5, 25, 50, 100, and 200 µM by diluting stock solutions with culture medium. HEp2
cells were exposed to the working solutions up to 200 µM with 24 h incubation (5% CO2 ,
95% humidity, 37 ◦ C). After 24 h treatment, the loading medium was removed, and cells
were washed thrive with phosphate buffered saline (PBS) solution to remove residual
compound. Then, medium containing 20% CellTiter Blue (CTB) (Promega, Madison, WI,
USA) was added to the cells and allowed to incubate it for another 4 h. Following the
incubation period, cell viability was assessed by determining fluorescence intensity at
570/615 nm using a BMG FLUOstar Optima microplate reader (BMG Labtech, Cary, NC,
USA). The fluorescence intensity was normalized to 100% for untreated cells and the results
are expressed as a percentage of viable cells.
3.4.2. Phototoxicity
HEp2 cells were exposed to working solutions of each compound up to 100 µM (0,
3.125, 6.25, 12.5, 25, 50, and 100 µM) and incubated for 24 h (5% CO2 , 95% humidity, 37 ◦ C).
The loading medium was removed and the cells were washed with PBS solution. Fresh
culture medium was introduced to the cells, followed by light exposure using a halogen
lamp (600 W) light source that included a beam turning mirror (200 nm to 30 µm spectral
range, Newport) and a water filter (transmits radiation 250–950 nm), for 20 min. The cells
received a total light dose of approximately 1 J·cm−2 . After 20 min light exposure, the cells
were returned to the incubator for another 24 h. The culture medium was replaced with
media containing 20% CellTiter Blue and the cells incubated for 4 h. Cell viability was
assessed as described above.
3.4.3. Time-Dependent Cellular Uptake
Cellular uptake was investigated in HEp2 cells exposed to 10 µM solutions of compounds 1, 2, 3, 4, and 5 at incremental time intervals (0, 1, 2, 4, 8, and 24 h). At the end
of the allotted time, the loading medium was removed, and the cells washed with PBS
solution to remove residual compound not taken up by the cells. Cells were solubilized
using 0.25% Triton X-100 in PBS. Compound standard curves were created by diluting the
32 mM stock solutions with 0.25% Triton X-100 in PBS to final concentrations of 10, 5, 2.5,
1.25, 0.625, and 0.3125 µM. A cell standard curve was created by plating 10,000, 20,000,
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40,000, 60,000, 80,000, and 100,000 cells per well (five replicates for each concentration).
To quantify cells, CyQuant Cell Proliferation Assay (Invitrogen, Carlsbad, CA, USA) was
used. The concentration of the compounds was determined using the standard curves and
a BMG FLUOstar Optima microplate reader at 485/520 nm. Cellular uptake results are
expressed in nM of compound per cell.
3.4.4. Competitive Binding Studies
Cells HT-29 (~78% EGFR) DLD-1 (~37% EGFR) and LOVO (~6% EGFR) with high,
moderate, and low EGFR expressions, respectively, were used in these studies. About
ten thousand cells of each cell line were coated in a 96 well clear bottom tissue culture
black plate and incubated overnight at 37 ◦ C with 5% CO2 . After 24 h, the medium was
removed, and different concentrations (0.25 to 100 µM) of cyclo(K(N3 )larllt) with a constant
concentration (50 µM) of conjugate 5, was added to the wells in triplicate. PBS was used
for dilution of compounds. The plate was then covered in aluminum foil and incubated at
37 ◦ C with 5% CO2 . After 45 min, each well was washed twice with 100 µL of PBS, and
fluorescence was determined with a microplate reader using an excitation wavelength of
614 nm and an emission wavelength of 648 nm. Autofluorescence values were subtracted
from each well. A plot of concentrations vs. relative fluorescence was plotted. Results in
Figure 4 are expressed as ±S.E.
4. Conclusions
Two terminal alkyne-functionalized BODIPY dyes and two EGFR azido-peptide ligands, one linear and one cyclic, were conjugated via click chemistry in 70–82% yields. Of all
the conjugates, 4 and 5 bearing an indolyl styryl group showed increased cellular uptake
and cytotoxicity compared with 3, which bears no indolyl styryl group. However, the
presence of the cyclic peptide in conjugate 5 induced the highest accumulation in HEp2
cells that overexpress EGFR of all compounds in this series. This might be a result of the
more rigid conformation of the cyclic peptide, which is more suitable for binding to EGFR,
compared with the linear peptide. SPR results suggest that all conjugates bind to EGFR, in
particular, conjugate 5. Competitive binding studies using three cell lines with different
EGFR expression showed that conjugate 5 specifically binds to colon cancer cells overexpressing EGFR (HT-29), while non-specific binding was also observed in cells with low
EGFR expression (LOVO). The click conjugation of fluorophores to azide-functionalized
peptides is anticipated to provide a resourceful methodology for the preparation of vast
arrays of functionalized BODIPYs possessing potential utility in in vivo imaging.
Supplementary Materials: The following are available online, Figure S1: HPLC for 3, Figure S2:
HPLC for 4, Figure S3: HPLC for 5, Figure S4: MALDI-TOF for 3, Figure S5: MALDI-TOF-TOF for
3, Figure S6: MALDI-TOF for 4, Figure S7: MALDI-TOF-TOF for 4, Figure S8: MALDI-TOF for 5,
Figure S9: MALDI-TOF-TOF for 5, Figure S10: SPR sensorgram for 3, Figure S11: SPR sensorgram
for 4, Figure S12: SPR sensorgram for 5, Figure S13: 1 H-NMR spectrum for 3, Figure S14: HSQC
NMR spectrum for 3, Figure S15: 1 H-NMR spectrum for 4, Figure S16: HSQC NMR spectrum for 4,
Figure S17: 1 H-NMR spectrum for 5, Figure S18: HSQC NMR spectrum for 5, Figure S19: Normalized
UV-Vis and fluorescence spectra, Figure S20: Phototoxicity results in human HEp2 cells.
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